[Bortezomib in combination with dexamethasone for relapsed multiple myeloma]
>>Leuk Res. 2005 May;29(5):587-90. Epub 2005 Jan 15.
Bortezomib in combination with dexamethasone for relapsed multiple myeloma.
Kropff MH, Bisping G, Wenning D, Volpert S, Tchinda J, Berdel WE, Kienast J.
Department of Medicine/Hematology and Oncology, University of Munster, Albert-Schweitzer-Str. 33, 48149 Munster, Germany.
Fifteen patients with advanced multiple myeloma were scheduled to receive bortezomib 1.3mg/m(2) IV days 1, 4, 8, and 11 every 3 weeks for eight cycles in combination with dexamethasone. One patient (7%) achieved a complete response, 10 (67%) a partial response, and one (7%) a minor response (MR) resulting in an overall response rate (>/=MR) of 80% (9/9 with >/= 2nd untreated and 3/6 with refractory relapse). Responses occurred after a median of 3 weeks and were independent of conventional prognostic parameters including deletion of chromosome 13. Adverse events, mainly myelosuppression, neuropathy and fatigue, were manageable.<<
OT: Looks like you win the 1st round with your call on XYOTAX, notes or no notes. Thanks for the heads up!
Cheers, Tuck |
